So I do believe that combining claudin 18.2-directed therapy with checkpoint inhibition, this is already an ongoing trial, in the LUCERNA trial, this could be very interesting to see what the added value of zolbetuximab will be in that setting in a CPS higher population. And secondly, I do think that combining HER2-directed therapy with anti-CLDN-directed therapy like PI3K-specific targets can be of interest...
So I do believe that combining claudin 18.2-directed therapy with checkpoint inhibition, this is already an ongoing trial, in the LUCERNA trial, this could be very interesting to see what the added value of zolbetuximab will be in that setting in a CPS higher population. And secondly, I do think that combining HER2-directed therapy with anti-CLDN-directed therapy like PI3K-specific targets can be of interest. The only thing that we have to take into account is while we add more antibodies, costs will be incrementally high and then we have to be very careful not to give too many antibodies that the government cannot afford paying for all these antibodies in a first-line.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
